Dashenlin Pharm Grp Co Ltd Working Capital to Net Assets Ratio
Dashenlin Pharm Grp Co Ltd working capital to net assets ratio. Dashenlin Pharm Grp Co Ltd (603233) has a Working Capital to Net Assets ratio of -11.9% as of March 2026. Working capital of CN¥-1.09 Billion (current assets of CN¥13.88 Billion minus current liabilities of CN¥14.97 Billion) is measured against net assets of CN¥9.18 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check tangible net worth ratio of Dashenlin Pharm Grp Co Ltd to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Dashenlin Pharm Grp Co Ltd (2012–2025)
Working capital to net assets ratio of Dashenlin Pharm Grp Co Ltd from 2012 to 2025. This chart shows how Dashenlin Pharm Grp Co Ltd's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of March 2026, the ratio stands at -11.9%, reflecting working capital of CN¥-1.09 Billion against net assets of CN¥9.18 Billion CNY. See 603233 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Dashenlin Pharm Grp Co Ltd Working Capital to Net Assets Ratio by Year (2012–2025)
Dashenlin Pharm Grp Co Ltd working capital to net assets ratio by year from 2012 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Dashenlin Pharm Grp Co Ltd from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Dashenlin Pharm Grp Co Ltd assets under control.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -19.5% | CN¥-1.69 Billion | CN¥8.66 Billion | CN¥13.38 Billion | CN¥15.07 Billion | ▼ -5.7 pp |
| 2024 | -13.8% | CN¥-1.12 Billion | CN¥8.14 Billion | CN¥12.59 Billion | CN¥13.71 Billion | ▼ -5.5 pp |
| 2023 | -8.3% | CN¥-655.27 Million | CN¥7.93 Billion | CN¥10.80 Billion | CN¥11.45 Billion | ▼ -22.3 pp |
| 2022 | 14.0% | CN¥962.03 Million | CN¥6.86 Billion | CN¥10.67 Billion | CN¥9.71 Billion | ▲ +2.4 pp |
| 2021 | 11.7% | CN¥692.26 Million | CN¥5.94 Billion | CN¥7.87 Billion | CN¥7.18 Billion | ▼ -39.1 pp |
| 2020 | 50.8% | CN¥2.83 Billion | CN¥5.57 Billion | CN¥8.30 Billion | CN¥5.47 Billion | ▲ +16.9 pp |
| 2019 | 33.8% | CN¥1.47 Billion | CN¥4.33 Billion | CN¥5.47 Billion | CN¥4.00 Billion | ▲ +14.0 pp |
| 2018 | 19.8% | CN¥611.04 Million | CN¥3.09 Billion | CN¥4.03 Billion | CN¥3.41 Billion | ▼ -17.9 pp |
| 2017 | 37.7% | CN¥1.06 Billion | CN¥2.80 Billion | CN¥4.05 Billion | CN¥3.00 Billion | ▲ +22.1 pp |
| 2016 | 15.7% | CN¥210.47 Million | CN¥1.34 Billion | CN¥2.40 Billion | CN¥2.19 Billion | ▼ -11.2 pp |
| 2015 | 26.9% | CN¥274.47 Million | CN¥1.02 Billion | CN¥1.82 Billion | CN¥1.54 Billion | ▲ +25.2 pp |
| 2014 | 1.6% | CN¥9.42 Million | CN¥574.85 Million | CN¥1.69 Billion | CN¥1.68 Billion | ▼ -17.3 pp |
| 2013 | 18.9% | CN¥111.54 Million | CN¥589.93 Million | CN¥1.19 Billion | CN¥1.08 Billion | ▼ -31.8 pp |
| 2012 | 50.7% | CN¥193.24 Million | CN¥381.11 Million | CN¥808.28 Million | CN¥615.04 Million | — |